Elekta (EKTA-B.ST)

Executive Summary

Elekta is a leading Swedish medical technology company that has specialized in precision radiation medicine for over 50 years. The company develops advanced radiotherapy, radiosurgery, and software systems aimed at treating cancer and brain disorders with high accuracy while minimizing damage to healthy tissue. With a market capitalization of approximately $2.1 billion and a global presence, Elekta competes with companies like Varian (now part of Siemens Healthineers) and Accuray. Its core products include the Elekta Unity MR-linac, which integrates magnetic resonance imaging with radiotherapy for real-time tumor tracking, and the Elekta Esprit linear accelerator. The company's mission is to make adaptive radiotherapy a practical standard of care worldwide, supported by a growing installed base and recurring software revenue. Recent strategic initiatives have focused on expanding into emerging markets and enhancing digital offerings through AI-driven treatment planning. Elekta's financial performance has shown steady revenue growth, though profitability remains under pressure due to R&D investments and competitive pricing. The company is well-positioned to benefit from the increasing global incidence of cancer and the shift towards more precise, personalized treatments. Key upcoming catalysts include potential FDA clearance for next-generation software platforms, expansion of partnerships in Asia, and possible shareholder returns from improved cash flow. Overall, Elekta's leadership in MR-guided radiotherapy and commitment to innovation support a positive long-term outlook.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance of Elekta Unity Next-Gen Software Suite75% success
• Q2 2026Major Partnership in Asia-Pacific for Radiosurgery Expansion60% success
• Q2 2026Release of Q4 FY2026 Earnings with Improved Operating Margin70% success